Q/C TECHNOLOGIES, INC. (QCLS): Nasdaq/NYSE listing notice — TNF Pharma receives Nasdaq bid price deficiency notice; 180 days to cure

Q/C TECHNOLOGIES, INC.

Received Nasdaq letter on March 17, 2025 for failure to maintain minimum $1.00 bid price over 30 consecutive business days.
Compliance period of 180 calendar days until September 15, 2025; must have $1.00 closing bid for 10 consecutive days.
If not cured, may get additional 180 days by meeting other listing standards and providing intent to cure, e.g., reverse stock split.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

Q/C TECHNOLOGIES, INC. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

March 17, 2025, TNF Pharmaceuticals, Inc. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share (“Common Stock”), for the 30 consecutive business days between January 30, 2025, to March 14, 2025, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with

View on SEC.gov

Browse all listing & compliance notices →

Q/C TECHNOLOGIES, INC. filing history →

Source: SEC EDGAR

accession 0001493152-25-011160

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.